Lee-Jah Chang | Head of Clinical Development, Vaccines and Immune Therapies
AstraZeneca

Lee-Jah joined AZ in 2021 and currently is the Vice President, Head of Clinical Development for V&I where he leads the Early and Late V&I clinical teams supporting the clinical development strategy for our vaccine and monoclonal antibody programs. Previously, he was the Head of Early Clinical Strategy and the Global Clinical Head, focusing on the early stage pipeline programs and FluMist.   Prior to joining AZ, Lee-Jah was a Global Clinical Lead at Sanofi where he led 8 vaccine programs including Fluzone High-Dose Quadrivalent, taking this vaccine from Phase 1 studies through to global licensure and launch. Lee-Jah is double board certified and completed his allergy and immunology fellowship at the National Institutes of Health in Bethesda, Maryland, and internal medicine residency at Northwestern McGaw Medical Center in Chicago.